In this section
@article{Massen:2025:eurjpc/zwaf068,
author = {Massen, G and Stone, PW and Jenkins, RG and Allen, RJ and Wain, LV and Stewart, I and Tayal, U and Quint, J and DEMISTIFI, consortium},
doi = {eurjpc/zwaf068},
journal = {European Journal of Preventive Cardiology},
title = {The association between fibrotic diseases and treatment resistant hypertension in England},
url = {http://dx.doi.org/10.1093/eurjpc/zwaf068},
year = {2025}
}
TY - JOUR
AB - AimsMultimorbidity has been identified as a research priority in recent years; fibrosis (progressive organ scarring) is one mechanism that may underpin multimorbidity. Some studies suggest hypertension could be fibrotic, particularly severe hypertension (uncontrollable with medications); however, it is not currently known whether severe hypertension is associated with fibrotic conditions. The objective is to investigate whether treatment-resistant hypertension is associated with fibrotic conditions.Methods and resultsWe used the Clinical Practice Research Datalink Aurum primary care database to define a cohort of people with hypertension during 2015. We determined the percentage of people who had conditions with fibrotic manifestations and explored differences respective to hypertension control. We applied multivariable logistic regression to analyse associations (P < 0.001) between hypertension control and each fibrotic condition, respectively. Of 1 340 495 people with hypertension during 2015, 83.50% (n = 1 119 333) had managed hypertension either by lifestyle or by medication; 16.50% (n = 221 162) had treatment-resistant hypertension. Fibrotic conditions were more common {75.40% [95% confidence interval (CI): 75.20–75.60] vs. 68.90% (95% CI: 68.81–70.01)} in people with treatment-resistant hypertension compared with those with managed hypertension. We found that treatment-resistant hypertension was associated with cardiomyopathy (ORadj: 1.85, 95% CI: 1.81–1.90), both Type 1 and Type 2 diabetes (ORadj: 1.49, 95% CI: 1.44–1.55, ORadj: 1.61, 95% CI: 1.60–1.63, respectively), liver fibrosis (ORadj: 1.52, 95% CI: 1.46–1.58), valve fibrosis (ORadj: 1.41, 95% CI: 1.37–1.44), and urinary fibrosis (ORadj: 1.41, 95% CI: 1.36–1.47).ConclusionThe proportion of people with fibrotic conditions was greater in those with treatment-resistant hypertension than managed hypertension. The identified associations between treatment-res
AU - Massen,G
AU - Stone,PW
AU - Jenkins,RG
AU - Allen,RJ
AU - Wain,LV
AU - Stewart,I
AU - Tayal,U
AU - Quint,J
AU - DEMISTIFI,consortium
DO - eurjpc/zwaf068
PY - 2025///
SN - 2047-4873
TI - The association between fibrotic diseases and treatment resistant hypertension in England
T2 - European Journal of Preventive Cardiology
UR - http://dx.doi.org/10.1093/eurjpc/zwaf068
ER -